Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?

Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?

Source: 
Endpoints
snippet: 

In the run up to the Hong Kong stock exchange’s anticipated rule change — opening the door for Chinese pre-revenue biotechs to go public closer to home — more than a year ago, Tasly Biopharma was one of the big players whose rumored interest helped stoke enthusiasm for the new listing venue. The company has since kept the drumroll rumbling in the background, raising a pre-IPO round and convincing partner Transgene to swap ownership in a joint venture for equity.